Dr Spike Willcocks
Chief BD Officer
After completing an MA in Chemistry and a DPhil in Biochemistry at the University of Oxford, Dr Willcocks became one of the initial members of IPGroup Plc following its landmark deal with the Chemistry Department at Oxford. Ultimately leading the Life Science team, Dr Willcocks' role encompassed all aspects of technology commercialisation, including spin-out company formation and business and corporate development, as well as private and public equity financings.
Dr Willcocks was a key player in the creation of 14 life science businesses based on technology from three universities, leading proposals for the investment of £4m in seed financing from IPGroup and holding positions of Director and Chairman for 6 portfolio companies. Working alongside the executive teams of the portfolio companies, Dr Willcocks played an integral role in out-licensing transactions, co-development deals and acquisitions. As well as supporting fundraisings for portfolio biotechnology companies, raising an aggregate of £20m, Dr Willcocks also assisted with IPGroup's own IPO in October 2003 on the LSE, raising £30m and capitalising the company at over £100m. Dr Willcocks was actively involved in the establishment of ONL whilst at IPGroup before joining full time in January 2006.
He is also a leading real tennis player, and regularly competes in international tournaments.
Jim McDonald is Finance Director at Oxford Nanopore Technologies. He joined the Company on 12 May 2009 and was appointed as a Director on 19 May 2010. With both a legal and financial reporting background, he has significant financial management experience gained working in the medical device and healthcare industry. Prior to joining the company, he was Finance Director at Abbott Diabetes Care Limited, providing financial management support as the company went from being venture capitalist funded to being listed on the NASDAQ exchange and ultimately being acquired by Abbott Laboratories, a multi-national pharmaceutical and medical diagnostics company.
Jim completed his accountancy training at Andersens, working in Denver and in the Technology and Corporate Services division in London; leading accounting, business advisory and tax services to a portfolio of international high technology and bio-medical clients. Previously, he practiced law with a Colorado law firm representing commercial and industrial banks specialising in secured transactions and commercial litigation. Jim holds a law degree, is a licensed attorney and qualified as a Certified Public Accountant in Colorado.
Dr Gordon Sanghera
Chief Executive Officer
Gordon Sanghera was co-founder of Oxford Nanopore, together with Hagan Bayley and IP Group. He was appointed CEO in June 2005. He brings over 20 years' experience in the design, development and global launch of disruptive platform sensor technologies.
Dr Sanghera’s PhD in bioelectronics sensing was followed by a career at MediSense an Oxford spin-out that delivered a new generation glucose technology to the market. Following the acquisition of MediSense by Abbott Laboratories Dr Sanghera held both UK and US VP and Director-level positions, including VP World Wide Marketing, Research Director and Manufacturing Process Development Director. Before its acquisition by Abbott, Gordon led the R&D of Medisense Inc. where he was instrumental in the launch of several generations of blood glucose bio-electronic systems for the consumer and hospital medical markets. He has also developed and validated production processes to meet with the regulatory requirements for USA and Europe.
Gordon has a PhD in bio-electronic technology and a degree in Chemistry.
Read the article about Dr Sanghera in the Financial Times.
Alan is the Chief Executive Officer of IP Group plc, a company that invests in and builds technology businesses based on intellectual property, primarily from its research intensive partner universities. IP Group offers more than traditional venture capital, providing its companies with access to business building expertise, networks, recruitment and business support. Its portfolio comprises holdings in over 70 companies, ranging from early stage to mature businesses across five main sectors.
Alan was the joint founder and Chief Executive of Techtran Group Ltd, the first company in Europe to offer a complete outsourced technology transfer function to universities. Techtran was acquired by IP Group in 2005. Alan is also Non-Executive Chairman of Proactis, an AIM-listed software company based in York. From 1995-2002 Alan was a partner in KPMG where he specialised in providing advice to fast growing technology businesses. Alan holds a BA in Economics from the University of Leeds and a MBA with Distinction from the University of Bradford. He is a fellow of the Institute of Chartered Accountants of England and Wales. Alan is also a non-executive director of the Department for Business, Innovation & Skills (BIS) and Chairman of its Audit Committee.
Peter Allen ACA
Peter Allen joined the board of Oxford Nanopore in 2011, bringing broad, senior experience in the life sciences industries. He currently serves as Chairman on the Boards of Non-Executive Chairman on the Boards of Group plc (AIM listed), Future plc (LSE listed), Advanced Medical Solutions plc (AIM listed), Chroma Therapeutics Ltd (private equity owned) and Non-Executive Director on the boards of Mecom plc (LSE listed), Scancell plc (AIM listed).
Previously, Peter was Chief Financial Officer of the electronics company Abacus Group plc from April 2005 until the company was sold to Avnet Inc in January 2009. Prior to this he was Chief Financial Officer of Celltech Group plc between 1992 and 2004. In addition to managing Celltech's flotation process in 1993, Peter played a key role in several strategic acquisitions, including Chiroscience Group plc, Medeva plc and Oxford Glycosciences plc. In 2003 Peter was also appointed Deputy Chief Executive Officer of Celltech until the company was sold to UCB in 2004.
Sarah Gordon Wild
Sarah Gordon Wild worked on Wall Street from 1986-2003, where her roles included being a biotechnology analyst at Greig Middleton, Kleinwort Grieveson,Hambrecht and Quist and Amerindo Investment Advisors. She was subsequently an analyst and portfolio manager at Lone Pine Capital where she focused on biotechnology, device and pharmaceutical companies. Sarah has a lifelong interest in how technology and healthcare products progress through research & development to commercialisation, and differences between the UK and US.
She now lives in the UK and has consulted in the Hedge Fund business. Sarah also serves on the Board of Lone Pine Capital Offshore Funds, Duke’s Auctioneers Ltd and Leweston School Board of Governors.